This Stock Blog gives insight on daily stock market trading as well as stock trading analysis and technical analysis of the Stock Market and individual stocks making the news.
Monday, March 11, 2013
Titan Pharmaceuticals Schedules Conference Call
Titan Pharmaceuticals, Inc.
today announced that it
will host a live conference call at 8 a.m. PT / 11 a.m. ET on Monday,
March 18, 2013. Titan will provide the Company's financial results as
of December 31, 2012. The call will be hosted by Sunil Bhonsle,
president, Katherine Glassman-Beebe, Ph.D., executive vice president
and chief development officer, Brian Crowley, vice president of
finance and Marc Rubin, M.D., executive chairman.This will probably be bad news for TTNP.I sold my shares today at $1.74.To much of a gamble to hold my shares best of luck everyone holding.
ZGNX Rejection coming
The Advisory Panel vote was an 11-2 AGAINST approval. The FDA will give
a CRL for sure. The FDA is looking for products that have a delivery
system that prevents abuse. They just had a special meeting on abuse of
sustained release products and the consensus was that not enough was
being done to prevent abuse. The decision to delay was made so they
could formulate a CRL letter that is consistent with the findings of the
meeting. If you are in this stock, you better get out before it goes
back to 75 cents. I shorted another 5000 shares at $1.95 today.
Wednesday, March 6, 2013
TTNP Big day less than 2 weeks
Titan Pharmaceuticals big day is coming 03/21/2013 advisory committee meeting.
The Company’s New Drug Application (NDA) for Probuphine® for the maintenance treatment of adult patients with opioid dependence.Keep an eye on this one can get a nice little pop over the next week.I still have my shares from $1.38.Looking to unload them over the next week and a half.Don't want to hold them,might end up like ZGNX.If the vote is positive this could be bad for Zogenix stock holders over the next couple of weeks.
GLTA
The Company’s New Drug Application (NDA) for Probuphine® for the maintenance treatment of adult patients with opioid dependence.Keep an eye on this one can get a nice little pop over the next week.I still have my shares from $1.38.Looking to unload them over the next week and a half.Don't want to hold them,might end up like ZGNX.If the vote is positive this could be bad for Zogenix stock holders over the next couple of weeks.
GLTA
Monday, March 4, 2013
DEPO Denied
The FDA panel, in a 13-to-1 vote, overwhelmingly ruled against Depomed's drug,
saying clinical data failed to show the product was effective. Then the panel,
in a 12-to-2 vote, ruled the overall risk-benefit profile wasn't acceptable to
support marketing of the product. The panel, which is made up of non-FDA medical
experts, will vote on Hisamitsu's drug later Monday.
Looking for a quick short and a little bounce at the open
Looking for a quick short and a little bounce at the open
Saturday, March 2, 2013
March FDA events
March FDA events
This is a list of biotech company's upcoming events that I will be keeping an eye on.
DEPO Advisory committee meeting on the 03/04/13
NRIFF PDUFA date for Pennsail on 03/04/13
THRX Advisory committee meeting on the 03/07/13
ANAC Phase 3 result of Tavaborole out around the 3/12/13
TTNP Advisory committee meeting on the 03/21/13
APPA PDUFA date for APF530 on 3/27/13
ZIOP Phase 3 result of palifosfamide around the 03/29/13
ACRX Phase 3 result of Sufentanil around the 03/31/13
ALIM Will be resubmitting the NDA for lluvien around the 03/31/13
CYCC Phase 3 results for Sapacitabine around the 03/31/13
IGXT NDA filing for Rizatriptan on 03/31/13
Subscribe to:
Posts (Atom)